S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer|
|Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics|
|Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398|
|Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer|
|Astrotech’s 1st Detect Announces European CE Certification for MMS-1000™|
|Investor Alert: Holzer & Holzer Announces Class Action Filed on Behalf of Investors in Millennial Media Inc. (2014/10/1)|
|Whiting Petroleum Corporation Announces Third Quarter 2014 Financial and Operating Results|
|Enterprise Prices $2.75 Billion of Senior Unsecured Notes|
|Strategic alliance with ATEC Rail Group (2014/11/27)|
|Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research|
Click above to view more mutual fund data and stats for mms - McMillan Shakespeare Ltd.